Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple MyelomaDavid H. Henry, Howard Yeh, Luís Costa et al.|Journal of Clinical Oncology|2011Cited by 1.3k
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma FoundationBrian G.M. Durie, Brian Van Ness, Angelina Rodrique Morales et al.|The Hematology Journal|2003Cited by 425
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trialShaji Kumar, Philippe Moreau, Simon J. Harrison et al.|The Lancet Oncology|2020Cited by 401
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working GroupPhilippe Moreau, Jean‐Luc Harousseau, Shaji Kumar et al.|The Lancet Oncology|2021Cited by 266
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumorsDavid H. Henry, Howard Yeh, Saroj Vadhan‐Raj et al.|Supportive Care in Cancer|2013Cited by 182